Virulizin(R) stimulates production of the antitumor protein TNFalpha
The article titled "Virulizin(R), a novel immunotherapy agent, stimulates TNFalpha expression in monocytes/macrophages in vitro and in vivo." was published in the journal International Immunopharmacology (volume 7, issue 10, pages 1350-9).
The study revealed that treatment with Virulizin(R) resulted in a significant induction of the cytokine TNFalpha in tumors in a mouse model of malignant melanoma. Virulizin(R) also stimulated production of TNFalpha in human macrophages in vitro. Importantly, a direct relationship between TNFalpha production by Virulizin(R) and cytotoxic activity towards cancer cells was demonstrated.
TNFalpha is a protein that is produced by cells of the immune system, particularly macrophages, which then activate other immune cells to attack tumor cells. The anticancer properties of TNFalpha are well known, and have been studied in both preclinical and clinical settings. These new findings confirm initial studies indicating that TNFalpha can contribute to the antitumor mechanism of Virulizin(R).
Virulizin(R) is a novel biological response modifier (or
immunotherapeutic agent) that stimulates a patient's immune system through
several mechanisms, including the activation of macrophages and the
infiltration of natural killer cells into tumors. In preclinical studies,
Virulizin(R) has demonstrated potential high levels of antitumor activity
against a number of cancer indications including pancreatic cancer.
Virulizin(R) has been granted orphan drug status and fast track status from
the United States FDA and orphan designation from the Marketing
Authorization Application with the European Medical Evaluation Agency
(EMEA). A drug that receives fast track designation must demonstrate that
it is intend
|SOURCE Lorus Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved